Reported 1 day ago
This article discusses a bullish perspective on argenx SE (ARGX), highlighting its potential for long-term growth despite recent sales challenges with the drug Vyvgart due to seasonal factors. The company's efforts in developing key treatments for autoimmune diseases and expanding its pipeline suggest a strong clinical value and market position. Despite short-term volatility, the author believes the current share price does not fully reflect the company's future growth potential, making it an appealing option for investors in innovative biotechnology.
Source: YAHOO